MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A

被引:157
|
作者
Ohta, Katsuya [1 ]
Hoshino, Hiromitsu [1 ]
Wang, Jinhua [1 ]
Ono, Shigeshi [1 ]
Iida, Yuuki [1 ]
Hata, Keisuke [1 ]
Huang, Sharon K. [1 ]
Colquhoun, Steven [2 ]
Hoon, Dave S. B. [1 ]
机构
[1] Providence St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA USA
[2] Cedars Sinai Med Ctr, Liver Dis & Transplant Ctr, Beverly Hills, CA USA
关键词
miR-93; hepatocellular carcinoma; drug-sensitivity; sorafenib and tivantinib; ALPHA-FETOPROTEIN; SIGNALING PATHWAY; CANCER; MELANOMA; CELLS; LIVER; IDENTIFICATION; INVOLVEMENT; MECHANISMS; SORAFENIB;
D O I
10.18632/oncotarget.3085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To assess the role of microRNAs (miR) in hepatocellular carcinoma (HCC), we performed comprehensive microRNA expression profiling using HCC cell lines and identified miR-93 as a novel target associated with HCC. We further verified miR-93 expression levels in advanced HCC tumors (n= 47) by a direct PCR assay and found that elevated miR-93 expression level is significantly correlated with poor prognosis. Elevated miR-93 expression significantly stimulated in vitro cell proliferation, migration and invasion, and additionally inhibited apoptosis. We confirmed that miR-93 directly bound with the 3' untranslated regions of the tumor-suppressor genes PTEN and CDKN1A, respectively, and inhibited their expression. As a result of this inhibition, the c-Met/PI3K/Akt pathway activity was enhanced. IHC analysis of HCC tumors showed significant correlation between c-Met protein expression levels and miR-93 expression levels. Knockdown of c-Met inhibited the activation of the c-Met/PI3K/Akt pathway regardless of hepatocyte growth factor (HGF) treatment, and furthermore reduced the expression of miR-93 in these HCC cells. miR-93 also rendered cells to be more sensitive to sorafenib and tivantinib treatment. We concluded that miR-93 stimulated cell proliferation, migration, and invasion through the oncogenic c-Met/PI3K/Akt pathway and also inhibited apoptosis by directly inhibiting PTEN and CDKN1A expression in human HCC.
引用
收藏
页码:3211 / 3224
页数:14
相关论文
共 50 条
  • [1] MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway
    Fu, Xiao
    Wen, Hongqing
    Jing, Li
    Yang, Yujuan
    Wang, Wenjuan
    Liang, Xuan
    Nan, Kejun
    Yao, Yu
    Tian, Tao
    CANCER SCIENCE, 2017, 108 (04): : 620 - 631
  • [2] MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling
    Cheng, Zhouyang
    Ni, Qingfeng
    Qin, Lei
    Shi, Yang
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2021, 54 (09)
  • [3] MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT signaling in hepatocellular carcinoma
    Tu, Kangsheng
    Liu, Zhikui
    Yao, Bowen
    Han, Shaoshan
    Yang, Wei
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 48 (03) : 965 - 974
  • [4] BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway
    Liu, Xueke
    Xie, Chunmei
    Li, Amin
    Zhang, Yinci
    Liu, Xinkuang
    Zhou, Shuping
    Shen, Jing
    Huo, Zhen
    Gao, Weiya
    Ma, Yongfang
    Xu, Ruyue
    Xing, Yingru
    Xie, Yinghai
    Cai, Shuyu
    Tang, Xiaolong
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2019, 11 (12): : 7255 - 7271
  • [5] Digoxigenin activates autophagy in hepatocellular carcinoma cells by regulating the PI3K/AKT/mTOR pathway
    Mengqing Ma
    Rui Hu
    Qi Huang
    Jing Li
    Minling Lv
    Jialing Sun
    Xin Zhong
    Jinyu Yi
    Lanfen Peng
    Wenxing Feng
    Wenfeng Ma
    Zhiyi Han
    Wei Zhang
    Xinfeng Sun
    Bolin Zhan
    Xingning Liu
    Xiaozhou Zhou
    Cancer Cell International, 24 (1)
  • [6] MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway
    Liu, Yang
    Tan, Juan
    Ou, Shuangyan
    Chen, Jun
    Chen, Limin
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 60 - 69
  • [7] Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
    Sun, Eun Jin
    Wankell, Miriam
    Palamuthusingam, Pranavan
    McFarlane, Craig
    Hebbard, Lionel
    BIOMEDICINES, 2021, 9 (11)
  • [8] Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
    Zhou, Qian
    Lui, Vivian W. Y.
    Yeo, Winnie
    FUTURE ONCOLOGY, 2011, 7 (10) : 1149 - 1167
  • [9] Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9
    Chen, Jing-song
    Wang, Qian
    Fu, Xin-hui
    Huang, Xiao-Hui
    Chen, Xi-lin
    Cao, Liang-qi
    Chen, Lian-zhou
    Tan, Hao-xiang
    Li, Wen
    Bi, Jiong
    Zhang, Long-juan
    HEPATOLOGY RESEARCH, 2009, 39 (02) : 177 - 186
  • [10] MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway
    Jiang, Jingjin
    Feng, Xiaoning
    Zhou, Wenjing
    Wu, Yue
    Yang, Yunmei
    ONCOTARGET, 2016, 7 (45) : 73188 - 73199